| 袁 玲,韩爱民,曹 杨,万雪媛,陈 敏.沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-III、CD5L以及炎症水平的影响[J].现代生物医学进展英文版,2022,(4):722-726. |
| 沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-III、CD5L以及炎症水平的影响 |
| Effects of Albuterol Combined with Budesonide Nebulized Inhalation on Serum AT-III, CD5L and Inflammation Levels in Children with Bronchial Asthma |
| Received:June 06, 2021 Revised:June 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.04.026 |
| 中文关键词: 沙丁胺醇 布地奈德 支气管哮喘 血清抗凝血酶Ⅲ CD5 抗原样蛋白 |
| 英文关键词: Salbutamol Budesonide Bronchial asthma Serum antithrombin Ⅲ CD5 antigen-like protein |
| 基金项目:江苏省妇幼保健协会科研项目（FYX202027） |
|
| Hits: 766 |
| Download times: 432 |
| 中文摘要: |
| 摘要 目的：探讨沙丁胺醇联合布地奈德雾化吸入对支气管哮喘患儿血清AT-III、CD5L以及炎症水平的影响。方法：选取我院2018年10月到2020年10月共收治的78例支气管哮喘患儿作为研究对象，将所有患儿随机分为观察组与对照组，每组39例。对照组患儿应用布地奈德雾化吸入治疗，观察组患儿应用沙丁胺醇联合布地奈德雾化吸入治疗，对比两组患儿的治疗效果、治疗前后的FeNO、肺功能指标、血气指标、血清AT-III、CD5L以及外周血单个核细胞NLRP3炎症小体变化情况。结果：观察组患儿的治疗总有效率为97.44%，显著高于对照组的82.05%（P＜0.05）；两组患儿治疗前PEF、FVC、FEV1指标对比无显著差异（P＞0.05），通过治疗后观察组患儿的PEF、FVC、FEV1指标明显优于对照组，组间对比，差异具有统计学意义（P＜0.05）；通过对比各项肺功能指标发现，两组患儿治疗后PaO2、PaCO2、SaO2指标对比差异均无统计学意义（P＞0.05）；两组患儿治疗前FeNO、AT-III、CD5L以及外周血单个核细胞NLRP3炎症小体表达对比无明显差异（P＞0.05）；治疗后，观察组患儿FeNO、AT-Ⅲ水平以及NLRP3 mRNA表达均显著低于对照组，CD5L水平高于对照组（P＜0.05）。结论：对支气管哮喘患儿应用沙丁胺醇联合布地奈德雾化吸入治疗，能够减轻患儿临床症状，提高治疗效果，提升患儿肺功能，稳定血气指标，减轻慢性缺氧状态，提升免疫力，降低炎症反应，值得临床应用推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of albuterol combined with budesonide nebulized inhalation on serum AT-III, CD5L and inflammation levels in children with bronchial asthma. Methods: A total of 78 children with bronchial asthma admitted to our hospital from October 2018 to October 2020 were selected as the research objects. All the children were randomly divided into an observation group and a control group, with 39 cases in each group. Children in the control group were treated with budesonide nebulized inhalation, and children in the observation group were treated with salbutamol combined with budesonide nebulized inhalation. The treatment effects of the two groups of children were compared, FeNO, the lung function indexes before and after treatment, blood gas indexes, and serum AT- III. Changes in CD5L and NLRP3 inflammasomes of peripheral blood mononuclear cells. Results: The total effective rate of treatment for children in the observation group was 97.44%, which was significantly higher than 82.05% in the control group (P＜0.05). The observation group was significantly higher than the control group. The difference between the groups was statistically significant (P<0.05). There was no significant difference in PEF, FVC and FEV1 indexes between the two groups before treatment (P>0.05). After treatment, PEF, FVC and FEV1 indexes of the observation group were significantly better than those of the control group, and the difference was statistically significant(P<0.05). By comparing various lung function indexes, There was no statistically significant difference in PaO2, PaCO2, and SaO2 between the two groups of children after treatment(P>0.05). Before treatment, there was no significant difference in FeNO, the expression of AT-III, CD5L and peripheral blood mononuclear cell NLRP3 inflammasome between the two groups of children(P>0.05). After treatment, the FeNO, AT-Ⅲ levels and NLRP3 mRNA expression of the observation group were significantly lower than those of the control group, and the CD5L level was higher than that of the control group(P<0.05). Conclusion: The application of salbutamol combined with budesonide nebulized inhalation therapy to children with bronchial asthma can reduce the clinical symptoms of the children, improve the treatment effect, improve the lung function of the children, stabilize blood gas indicators, reduce chronic hypoxia, improve immunity, and reduce Inflammation is worthy of clinical application and promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
